Compare with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CIPLA ALKEM LABORATORIES/
CIPLA
 
P/E (TTM) x - 19.6 - View Chart
P/BV x 8.0 2.2 366.6% View Chart
Dividend Yield % 0.5 0.7 73.4%  

Financials

 ALKEM LABORATORIES   CIPLA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CIPLA
Mar-19
ALKEM LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,589678 234.4%   
Low Rs1,232484 254.7%   
Sales per share (Unadj.) Rs417.5198.2 210.6%  
Earnings per share (Unadj.) Rs56.318.5 303.9%  
Cash flow per share (Unadj.) Rs64.735.0 185.0%  
Dividends per share (Unadj.) Rs12.703.00 423.3%  
Dividend yield (eoy) %0.90.5 174.3%  
Book value per share (Unadj.) Rs292.9186.3 157.2%  
Shares outstanding (eoy) m119.57805.70 14.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.9 115.3%   
Avg P/E ratio x25.131.4 79.9%  
P/CF ratio (eoy) x21.816.6 131.3%  
Price / Book Value ratio x4.83.1 154.4%  
Dividend payout %22.616.2 139.3%   
Avg Mkt Cap Rs m168,653468,031 36.0%   
No. of employees `000NA22.6 0.0%   
Total wages/salary Rs m9,17128,565 32.1%   
Avg. sales/employee Rs ThNM7,053.1-  
Avg. wages/employee Rs ThNM1,261.5-  
Avg. net profit/employee Rs ThNM659.1-  
INCOME DATA
Net Sales Rs m49,915159,710 31.3%  
Other income Rs m1,6454,766 34.5%   
Total revenues Rs m51,561164,475 31.3%   
Gross profit Rs m8,48230,973 27.4%  
Depreciation Rs m1,00613,263 7.6%   
Interest Rs m6711,684 39.8%   
Profit before tax Rs m8,45120,791 40.6%   
Minority Interest Rs m-114-172 66.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6065,695 28.2%   
Profit after tax Rs m6,73114,924 45.1%  
Gross profit margin %17.019.4 87.6%  
Effective tax rate %19.027.4 69.4%   
Net profit margin %13.59.3 144.3%  
BALANCE SHEET DATA
Current assets Rs m27,062124,266 21.8%   
Current liabilities Rs m15,32437,715 40.6%   
Net working cap to sales %23.554.2 43.4%  
Current ratio x1.83.3 53.6%  
Inventory Days Days6791 73.4%  
Debtors Days Days4195 43.5%  
Net fixed assets Rs m12,610105,190 12.0%   
Share capital Rs m2391,611 14.8%   
"Free" reserves Rs m34,490148,511 23.2%   
Net worth Rs m35,027150,123 23.3%   
Long term debt Rs m1,21238,301 3.2%   
Total assets Rs m54,387239,633 22.7%  
Interest coverage x13.613.3 101.9%   
Debt to equity ratio x00.3 13.6%  
Sales to assets ratio x0.90.7 137.7%   
Return on assets %13.66.9 196.4%  
Return on equity %19.29.9 193.3%  
Return on capital %24.911.8 210.0%  
Exports to sales %12.934.7 37.3%   
Imports to sales %3.10-   
Exports (fob) Rs m6,46155,419 11.7%   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56357,410 11.4%   
Fx outflow Rs m3,01219,041 15.8%   
Net fx Rs m3,55238,368 9.3%   
CASH FLOW
From Operations Rs m7,25916,911 42.9%  
From Investments Rs m1,864-16,687 -11.2%  
From Financial Activity Rs m-9,273-3,487 265.9%  
Net Cashflow Rs m-150-3,451 4.3%  

Share Holding

Indian Promoters % 66.9 16.0 418.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 33.1 12.2 271.3%  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 0.0 26.2 -  
Shareholders   68,381 161,166 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views on News

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Real Long-Term Impact of the Coronavirus on India(The 5 Minute Wrapup)

Mar 18, 2020

My view on the impact of the Coronavirus on the Indian economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 27, 2020 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS